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Alzheimer’s disease (AD) is the most common form of dementia found in all human populations worldwide, while vascular
dementia (VaD) is the second most common form of dementia. New biomarkers for early and speciﬁc diagnosis of AD and
VaD are needed to achieve greater insight into changes occurring in the brain and direct therapeutic strategies. The objective of
this explorative study was to discover candidate protein biomarkers for the diﬀerential diagnosis between VaD and AD. Surface-
enhanced laser desorption/ionization (SELDI) TOF-MS was used to diﬀerentially proﬁle proteins and peptides in CSF samples
from 28AD patients and 21 patients with VaD. A combination of univariate (Kruskal-Wallis) and multivariate (independent
component analysis) statistical approaches produced a list of 27 proteins and peptides that could diﬀerentiate between VaD and
AD.Thesemarkersrepresentvariousphysiologicalprocesses,suchasproteindegradation(ubiquitin),proteaseinhibition(cystatin
C and alpha-1-antichymoptrypsin), and inﬂammation (C3a and C4a) that are known to be represented in neurodegenerative
diseases.
1.Introduction
Alzheimer’sdisease(AD)isoneofthemostdevastatingbrain
disorders in the elderly. AD is a progressive neurodegen-
erative disease that represents the most common form of
dementia today [1]. Age is the single most prominent risk
factor with the incidence doubling every ﬁve years from the
age of 65 [2].
Vascular dementia (VaD) is a heterogeneous disorder
that accounts for about 20% of all cases of dementia.
Vascular dementia is characterized by neuronal death due
to vascular lesions such as lacunar, cortical or subcortical
infarcts, cerebral hemorrhage, and cardiogenic embolism,
contributing to cognitive decline [3].
Vascular dementia and Alzheimer’s disease frequently
occur together and they may often act in combination to
cause dementia and it is clinically challenging to separate
these two diseases.
Biomarkers that can aid in the diﬀerential diagnosis
between VaD and AD are relevant for several reasons. First,
the pharmacological treatment strategy diﬀers between the
two diseases since patients with VaD only beneﬁt modestly
if at all from cholinesterase inhibitors and memantine
which are the drugs used to treat AD. Since there are no
approved drugs for the treatment of VaD, current treatment
is limited to the control of known vascular risk factors,
such as hypertension and dyslipidemia [4]. Second, with
new AD disease modifying drugs being tested it is crucial to
diﬀerentiate between the patient groups for trial selection.
Third, from an epidemiologic point of view it is of utmost
importance that the clinical classiﬁcation is based on the
most up-to-date diagnostic practices in order to select the
most appropriate predictor variables and monitoring tolls.
The aim of this explorative study was to discover
candidate protein biomarkers for the diﬀerential diagnosis of
VaD and AD.2 International Journal of Proteomics
2.MaterialsandMethods
2.1. Study Subjects and Samples. Patients for this study were
recruited at University Hospital, ¨ Orebro, Sweden. They were
all referred to the Memory Care Unit at the Department
of Geriatrics for diagnostic assessment and treatment of
suspectedcognitiveproblems.AccordingtoSwedishresearch
ethics law no proxy could sign the informed consent papers
on behalf of the patient when collecting biobank material.
All patients in the study group underwent a structured and
thorough clinical investigation, including medical history,
family history and socioeconomic data, and physical as well
as neurological and psychiatric examination.
Considering the aim of this study, an important goal
was to include cases with as narrowly deﬁned diagnoses
as possible in order to exclude cases with possible mixed
AD/VaD, which would otherwise attenuate the diﬀerences
between the two groups.
Blood chemistry tests were done on all (see below).
Cerebrospinal ﬂuid (CSF) samples were obtained by lumbar
puncture at L3/L4 or L4/L5 level. The ﬁrst 10–12mL were
collected in polypropylene tubes. The lumbar puncture and
blood samples were collected at the same time, between 08
and10AMafterovernightfast.Thesampleswerecentrifuged
and supernatants stored in a biobank freezer at −80◦C.
The presence or absence of dementia was diagnosed
according to Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) criteria. Probable AD was diagnosed
accordingtoNationalInstituteofNeurologicalandCommu-
nicative Diseases and Alzheimer’s Disease and Related Disor-
ders Association (NINCDS-ADRDA) criteria [5], VaD was
diagnosed according to National Institute of Neurological
Disorders and Stroke and Association Internationale pour
la Recherch´ e et l’Enseignement en Neurosciences (NINDS-
AIREN) criteria [3]. Disease severity was assessed using
MMSE scores [6].
CSF samples (10–12mL) were obtained by lumbar punc-
ture, collected in polypropylene tubes, and gently mixed.
The samples were centrifuged at 2000×gf o r1 0 m i nt o
remove cells and other insoluble material. Supernatants were
frozen in aliquots and stored at −80◦C. To avoid blood
contamination, samples were discarded if they contained
more than 500 erythrocytes per μL.
The study was approved by the Regional Ethical Review
Board, Uppsala. All patients gave informed consent to
participate in the study, which was conducted in accordance
with the provisions of the Helsinki Declaration.
2.2. Laboratory Methods. CSF samples were thawed and 5μL
of each sample was diluted into 45μL of the appropriate
binding buﬀer for each of the ProteinChip Array types
(Ciphergen Biosystems, Fremont, CA, USA) using surface-
enhanced laser desorption/ionization time-of-ﬂight mass
spectrometry (SELDI-TOF-MS). The array types used were
CM10 and IMAC30 coupled with nickel and H50. To ensure
reproducibility of sample preparation and array analysis, a
reference CSF standard was randomly distributed in several
separate aliquots among the clinical samples and analyzed
under exactly the same conditions. Reproducibility was
measured by calculating average coeﬃcients of variation
(CV) for each set of acquisition parameters. All-array prepa-
ration was performed using a Biomek 2000 robot (Beckman
Coulter) and randomized sample placement. The samples
were allowed to bind for 60 minutes at room temperature.
Each array was washed three times with the appropriate
bindingbuﬀerandrinsedtwicewithwater.Energyabsorbing
molecule (EAM) application was performed automatically
using a modiﬁed Biodot AD3200 robot. Two aliquots of
0.75μL of solution containing 12.5mg/mL sinapinic acid
(SPA) in 50% acetonitrile, 0.5% triﬂuoroacetic acid (TFA)
wereappliedwithdryinginacontrolledatmospherebetween
applications. The arrays were read at two diﬀerent instru-
ment settings to focus on lower and higher masses. Each
samplewasruninduplicatesonseparatearraysonsuccessive
robot runs. All arrays were analyzed using a SELDI-TOF MS
ProteinChip Reader, series PCS4000 (Ciphergen Biosystems,
Fremont,CA,USA).Aproteinproﬁlewasgeneratedinwhich
individual proteins were displayed within spectra as unique
peaks based on their mass-to-charge ratio (m/z). Intensity
normalization was done by calculating the total ion current
for a spectrum, and the total ion current was then divided
by the number of data points for that spectrum to obtain
an average ion current for each individual spectrum. An
external coeﬃcient of 0.2 was chosen against which each
spectrumwasnormalized.Theverylowmassregioncontains
chemical“noise”fromthematrixandwasthereforeexcluded
from the analysis.
2.3. Puriﬁcation and Identiﬁcation of Candidate Markers.
Biomarkers were puriﬁed using combinations of chro-
matographic techniques employing a range of sorbents
(Pall corporation, NY, USA) typically followed by SDS-
PAGE. One-quarter of a gel band was extracted using
a solution containing 50% formic acid, 25% acetonitrile,
15% isopropanol, and 10% water and reanalyzed using the
ProteinChip Reader to conﬁrm their exact masses matched
with the original biomarker. The remaining three-quarters
of the band were in-gel digested with trypsin. Alternatively,
whole bands of interest were extracted from gels and
reanalyzed using the ProteinChip Reader to conﬁrm their
exact masses matched with the original biomarker. The gel-
extracted proteins were in-solution digested with trypsin.
Tryptic digests were analyzed by peptide mapping using the
ProteinChip Reader and by MS/MS using a Q-STAR XL
tandem mass spectrometer (AB Sciex) ﬁtted with a PCI-1000
ProteinChip Interface (Ciphergen Biosystems, Fremont, CA,
USA). Biomarkers smaller than 4kDa were enriched by
combinations of chromatographic techniques and identiﬁed
directly by tandem MS without SDS-PAGE puriﬁcation
and/or trypsin digestion.
Peptide mass ﬁngerprints and amino acid sequencing
results were entered into the Mascot database (http://www
.matrixscience.com) for protein identiﬁcation.
2.4.BioinformaticsandStatisticalMethods. ProteinChippro-
ﬁling spectral data were collected using CiphergenExpressInternational Journal of Proteomics 3
Table 1: Clinical Characteristics; values are means (SD).
Group (no.
samples)
Gender
M/F MMSE Age years
CSF
Aβ1-42
pg/mL
CSF total
Tau pg/mL
CSF phos-
phorylated
Tau pg/mL
CSF/serum
albumin ratio
CSF/serum
folate ratio
Total protein
g/L
28 probable AD 10/18 20.0
(3.7) 74.6 (11.4) 465 (146) 682 (316) 91 (36) 5.9 (1.7) 2.5 (0.9) 0.38 (0.11)
21 VaD 13/8 21.5
(2.6) 76.2 (8.4) 634 (169) 389 (185) 59 (24) 10.4 (5.5) 1.8 (1.2) 0.62 (0.33)
Mann-Whitney
P value n.s. n.s. 0.011 0.0007 0.0021 0.0005 0.0348 0.002
Table 2: Number of peaks and number of signiﬁcant peaks on the three array surfaces and the two mass ranges used.
Array type CM10 IMAC30-Ni H50
Peaks Signiﬁcant peaks Peaks Signiﬁcant peaks Peaks Signiﬁcant peaks
2–20kDa 78 38 50 5 38 3
20–200kDa 55 19 32 2 45 4
data management software version 3.0 (Ciphergen Biosys-
tems, Fremont, CA), where data handling and univariate
analysiswerealsoperformed.Allspectrawereinternallymass
calibrated and peak intensities were normalized using total
ion current.
All statistical analyses were conducted in R (http://www
.r-project.org/). The data structure complexity and redun-
dancy were reduced by identifying peak families (Spearman
correlation coeﬃcient ≥0.85) and retaining only the most
intense member. Comparisons were performed using a
Mann-Whitney test with a Benjamini-Hochberg (BH) cor-
rection for multiple testing. A signal processing algorithm,
independent components analysis (ICA), was applied to the
data set in addition to the two group comparison [7].
ICA decomposes the data matrix (E) into a component
matrix (C) comprised of the independent components (ICs)
and a mixing matrix (A) giving the linear mixing of each
IC in the samples. It is written as E = CA. An entry in
t h ec o m p o n e n tm a t r i xi sd e n o t e dal o a da n df o re a c hI C
the loads have a mean of zero and a standard deviation of
one. The fastICA package [8] was used to decompose data
by applying ICA and estimate the ICs. ICA was applied on
data a total of ﬁve times and the results from each run
weretestedforstabilitybycalculatinganabsolutecorrelation
coeﬃcient between the loads in each of the ICs with a set
of ICs obtained from 100 independent runs of fastICA [9].
In each of the 100 runs, the maximum absolute correlation
coeﬃcient was saved and only components with a mean
absolute correlation coeﬃcient ≥0.80 were retained. The
capability of each IC to separate the samples according to
classiﬁcation was tested using a Mann-Whitney test with
Benjamini-Hochberg correction for multiple testing. Peaks
fromsigniﬁcantcomponents(adjustedP value<0.05)having
absolute loads greater than 5 times the standard deviation
of the absolute loads were extracted as candidate peptide
biomarkers.
3. Results
In this study we analyzed CSF samples from 28 patients with
ADand21patientswithVaD(seeTable 1 forage,gender,and
MMSE).
Neither age nor MMSE was signiﬁcantly diﬀerent
between the AD and VaD groups with P values of 0.71 and
0.28 for age and MMSE, respectively.
As expected, levels of Amyloid Beta 1–42 were signiﬁ-
cantly decreased in patients with AD and levels of Total Tau
and Phosphorylated Tau were signiﬁcantly increased in the
same patient group compared to patients with VaD.
The albumin ratio was signiﬁcantly higher in patients
with VaD and the folate ratio was signiﬁcantly lower for the
same patient group as described before [10].
The SELDI intra-assay reproducibility of the discovery
method was measured on median peak intensities in 48
individual spectra from a reference CSF sample and found
to be between 14 and 19 percent CV (data not shown).
In Table 2 we describe the number of peaks found on
the three SELDI array surfaces as well as the number of
signiﬁcant peaks. The CM10 surface had considerably more
peaks, as well as signiﬁcant peaks, which are summarized in
Tables 3(a) and 3(b).
In total, eleven candidate biomarkers were obtained by
a two-group comparison (Table 3(a)). Independent compo-
nent analysis (ICA) gave rise to 21 signiﬁcant components
(Table 3(b)). There were six peaks in common between the
two methods. ICA has the power to extract single variables
or small groups of variables from a complex data set. The
components can be analyzed for a particular characteristic,
such as the ability to separate the two biological groups.
The combination of this method with a classical univariate
approach yielded a signiﬁcant number of proteins to con-
sider for further studies.
Unique peaks were found by analysis with ICA and
Mann-Whitney, which emphasizes the complementary eﬀect
of combining feature reduction approaches.4 International Journal of Proteomics
Table 3: Candidate biomarkers and signiﬁcant ICA components. Candidate biomarkers obtained from the univariate (a) and multivariate
(b) analysis are listed separately. The P values are Benjamini-Hochberg adjusted.
(a) Univariate analysis—Mann-Whitney
m/z Array type P value Direction of change in AD ID
8295 CM10 0,0017 ↑ Ubiquitin −3aa from CT
101801 CM10 0,0075 ↓
4352 CM10 0,0142 ↑ Alpha-1-antichymotrypsin CT fragment
4745 CM10 0,0142 ↑
66676 CM10 0,0142 ↓ Albumin
3515 CM10 0,0181 ↑ Neuroendocrine protein 7B2 CT fragment
17379 CM10 0,0181 ↓ ApoA-II dimer
2840 CM10 0,0186 ↑
8614 CM10 0,0274 ↑ C4a des-arg
4469 CM10 0,0305 ↑
2430 CM10 0,0387 ↑ Integral Membrane 2B CT fragment
(b) Multivariate analysis—ICA
m/z Array type P value Direction of change in AD ID
101801 CM10 0,0067 ↓
13105 CM10 0,0067 ↑
147523 CM10 0,0067 ↓ IgG
16207 CM10 0,0067 ↓
17379 CM10 0,0067 ↓ Apolipoprotein A-II dimer
28058 CM10 0,0067 ↓ Apolipoprotein A-I
66676 CM10 0,0067 ↓ Albumin
79578 CM10 0,0067 ↓ Transferrin
8936 CM10 0,0067 ↑ C3a des-arg
90294 CM10 0,0067 ↓
20934 CM10 0,0072 ↑ Retinol binding protein
4745 CM10 0,0072 ↑
51402 CM10 0,0077 ↓
3515 CM10 0,0104 ↑ Neuroendocrine protein 7B2 CT fragment
5262 IM30Ni 0,01076 ↓
6973 CM10 0,0159 ↑
73422 CM10 0,0182 ↑
2840 CM10 0,0255 ↑
15124 CM10 0,0347 ↓
2249 CM10 0,0467 ↓
13358 CM10 0,0471 ↑ Cystatin C
We found a total of 27 candidate markers; thirteen
of the proteins have been identiﬁed and are therefore of
special interest, see Tables 3(a) and 3(b). For representative
spectra for the best marker found by Mann-Whitney and
ICA, respectively, see Figures 1 and 2. Scatterplots of peak
intensities of these two peaks can be seen in Figure 3.
4. Discussion
In this exploratory study we aimed to discover potential
biomarkers that could distinguish between AD and VaD.
Since it is important in an exploratory discovery design to
avoid a type II error, we employed two diﬀerent methods for
feature selection [11–13]i no r d e rt oo b t a i nam o r ec o m p l e t e
list of candidate markers.
In the literature other biomarkers indicating diﬀerences
between AD and VaD have been described, such as albumin
index [14] and the CSF/Serum folate ratio, where a reduced
folate ratio was found to be a characteristic of dementia with
vascular component [10].
In our sample set, there were statistically signiﬁcant
diﬀerences in CSF levels of amyloid β1–42, total tau and
phosphorylatedtaubetweensamplesfrompatientswithVaD
and AD. However, several recently published large studiesInternational Journal of Proteomics 5
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Figure 1: Representative spectra of Ubiquitin −3 a af r o mC To nC M 1 0a r r a y .
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Figure 3: Scatter plot of peak intensities of Ubiquitin lacking 3 amino acids at the C-terminus left panel and the 101kDa marker right panel.6 International Journal of Proteomics
reportasubstantialoverlapbetweenthelevelsintheVaDand
AD groups [15].
We found a total of 27 candidate markers, thirteen
of which have been identiﬁed. We found both up- and
downregulated proteins in patients with VaD compared to
AD even if the CSF protein concentration was signiﬁcantly
higher in the VaD group. This could be explained by the
fact that we did ﬁnd elevated levels of albumin, IgG, and
transferrin, and these proteins comprise approximately 80%
of the CSF proteome [16].
Several of the markers found in this study were recog-
nized as markers that we have previously described in studies
of AD biomarkers and markers for progression to AD from
mild cognitive impairment (MCI) [17–19].
In our previous study we found decreased levels of the
CT fragment of Alpha-1-antichymotrypsin in AD compared
to healthy subjects [17]. Here we also found decreased levels
of the same fragment in the CSF of patients with VaD
compared to patients with AD. Thus it seems that levels
of this protease inhibitor are lowest in patients with VaD,
followedbypatientswithADandhighestinhealthycontrols.
We have previously found increased levels of the C-
terminal fragment of integral membrane 2B in the CSF of
AD and FTD patients compared to healthy controls [18],
increased levels of the full length protein have also been
described previously [20].
Integral membrane 2B is also known as a BRI peptide,
which is known to form insoluble deposits in the brains of
patients with familial British and familial Danish dementia
[21]. In this study we report reduced levels of the C-terminal
fragment of integral membrane 2B in the CSF of patients
with VaD compared to AD. Hence, the levels of this protein
are similar in patients with VaD and healthy controls but can
diﬀerentiate between patients with VaD and AD.
In our earlier studies we found increased levels of the
C3a peptide lacking the C-terminal arginine in the CSF
of patients with AD compared to healthy controls and in
patients with MCI who progressed to AD [17–19]. C3a is
partofthecomplementsystemandinvolvedininﬂammatory
processes. Here we show lower levels in the CSF of patients
with VaD compared to patients with AD. This means that
the levels of C3a des-arg in VaD are probably similar to the
levels in healthy controls. Hence this marker can diﬀerentiate
between VaD and AD but not between VaD and healthy
aging.
We have previously reported decreased levels of the
protease inhibitor Cystatin C in patients with AD compared
to healthy controls [17, 18]. In this study we ﬁnd that the
levels of Cystatin C are higher in patients with VaD than in
patients with AD. We postulate that the levels of Cystatin C
arelowestinpatientswithVaD,followedbypatientswithAD,
and highest in controls.
We have previously detected increased ubiquitin CSF
levels in patients with MCI who progressed to AD [19].
Increased CSF ubiquitin levels have previously been found
in both AD and VaD patients [22]. Here we show that VaD
patients had signiﬁcantly lower CSF concentrations of an
ubiquitin fragment lacking three C-terminal amino acids
compared to AD patients.
Neuroendocrine protein 7B2, also known as Secre-
togranin V is a molecular chaperone. To our knowledge
it has not been previously described in CSF samples from
patients with AD or VaD. Mattson et al. described increased
levels of Neuroendocrine protein 7B2 in the CSF of patients
with frontotemporal dementia (FTD) with high expression
of neuroﬁlament [23] In this study we found decreased levels
of this peptide in the CSF of VaD patients compared to AD
patients.
ApoA-I levels in CSF have previously been found to be
decreased in the CSF of AD patients when compared to
healthy controls [24, 25]; in this study we also ﬁnd decreased
levels in AD when comparing CSF from patients with AD to
patients with VaD.
In addition, we found increased levels of the dimer
of ApoA-II in the CSF of patients with VaD compared
to patients with AD. In the literature increased levels of
monomeric ApoA-II have been found in the CSF of patients
with AD compared to healthy controls [20, 26]. However, we
were not able to detect the monomeric form of ApoA-II in
our assay.
Higher levels of the complement pathway protein C4a
des-arghavebeendescribedpreviouslyintheCSFofpatients
with AD [20, 26], and our group also found increased levels
of the C4a peptide lacking the C-terminal arginine in MCI
patients who progressed to AD [19]. Here we ﬁnd higher
levels of the C4a des-arg peptide in the CSF of patients with
AD compared to VaD.
Several studies have described albumin as being signif-
icantly up- or downregulated in the CSF of AD patients
compared to healthy controls, see [27]f o rr e v i e w .H e r ew e
found albumin to be lower in patients with AD compared to
patients with VaD conﬁrming the clinically obtained data on
albumin ratios (Table 1). We also found lower levels of IgG
in the CSF of patients with AD compared to VaD. These two
proteins are used clinically to evaluate blood-brain barrier
impairment [28, 29], which is usually more impaired in VaD
than AD and consistent with higher Albumin and IgG levels
in the CSF of VaD patients.
Furthermore, we found lower levels of transferrin in AD
that could perhaps similarly be explained by blood-brain
barrier impairment in patients with VaD.
Conﬂicting results of the CSF levels of retinol binding
protein in patients with AD have been described. Increased
levels were reported in [20, 24] and in MCI patients who
progressed to AD [19]b u td e c r e a s e dl e v e l sw e r ef o u n di n
[25]. In the present study we found lower levels of Retinol
binding protein in the CSF of patients with VaD compared
to AD.
Presently, the occurrence of ischemic changes on com-
puted axial tomography (CAT) scan is a very helpful tool
to diﬀerentiate between AD and VaD patients. However, we
believe that the candidate biomarkers found in this study
could aid further in this diﬀerentiation.
We report both increased and decreased levels of several
proteins and peptides when comparing the CSF from
patients with VaD with the CSF from patients with AD.
These markers represent various physiological processes
such as protein degradation (ubiquitin), protease inhibitionInternational Journal of Proteomics 7
(Cystatin C and Alpha-1-antichymotrypsin), and inﬂamma-
tion (C3a and C4a) that are known to be represented in
neurodegenerative diseases.
In summary, we found a total of 27 candidate markers
for the diagnostic diﬀerentiation between VaD and AD.
Even for the markers with the lowest P values there was
considerable overlap between the two groups. Therefore we
do not expect any of these markers to be used on its own but
in combination with other markers such as the folate ratio,
levels of Amyloid Beta 1–42, total Tau, and phosphorylated
Tau. All of the thirteen markers identiﬁed in this study have
been described previously in the literature in the CSF of
patients with AD and MCI. To our knowledge, this is the ﬁrst
study where they are described in patients with VaD.
A limitation of the present study is the lack of a healthy
control group. Future studies should enroll pathology con-
ﬁrmed AD and VaD dementia cases as well as longitudinally
followed control individuals. Furthermore the diagnostic
performance of selected candidate markers from this study
s h o u l db ei n v e s t i g a t e di nl a r g ep r o s p e c t i v em u l t i c e n t e r
studies.
Despite the obvious application of these novel biomark-
ers to improve the accuracy of early diagnosis they could
also play a role in the development of new disease modifying
drugs. This and future proteomic and genomic explorations
ofclinicalsampleswilllikelyplayanimportantroleinunrav-
eling the biochemistry of dementia pathogenesis ultimately
leading to new therapeutic targets.
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